Thursday May 16 | Indianapolis Business News
Canada's Supreme Court won't hear Lilly appeal on Zyprexa
Canada's Supreme Court dismissed Eli Lilly and Co.'s request to appeal a federal court decision that invalidated its Canadian patent for schizophrenia drug Zyprexa.
These Stocks Are Still Solid Long-Term Picks
Jarrod is a member of The Motley Fool Blog Network -- entries represent the personal opinion of the blogger and are not formally edited.
Former Eli Lilly executive appointed to top technology post at Sears Holdings
Balagna was previously chief information officer for drug maker Eli Lilly and will be responsible for Sears Holdings' technology and infrastructure initiatives in its support centers and in-store. "Jeff is a proven executive with an analytic approach and experience in transforming complex organizations in rapidly evolving industries," Sears ... (more)
Brain League IP Services Adds a New Director to Its Board.
In a recent strategic move, Brain League added Mr. Erik Ramanathan to its board of directors.
National Center for Public Policy Res...
More on Eli Lilly and ObamaCare...
Eli Lilly CEO Dr. John Lechleiter Says Obama Administration "Dual-Eligibles" Rebate Plan Would Lead to "Catastrophic Consequences" for Innovation Industry Could Face More than $100 Billion in Extra Costs Under President's Plan, Lechleiter Says, in Response to Questioning from National Center for Public Policy Research Patients with Private ... (more)
Eli Lilly and Company Job Cuts Almost Double Original Numbers in Detailed Report
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! Eli Lilly and Co.'s massive restructuring of its sales force will affect more employees than the Indianapolis-based drugmaker disclosed in early April.
Eli Lilly and Company Declares Second-Quarter 2013 Dividend
Headquartered in , Lilly provides answers through medicines and information for some of the world's most urgent medical needs.
Eli Lilly: CEO Lechleiter will have aorta surgery
Drugmaker Eli Lilly & Co. said Tuesday that President, CEO and Chairman John Lechleiter will have surgery for a dilated aorta on Monday.
Send Press Releases with GlobeNewswire
Effective November 12, 1998, Chrysler common stock will be excluded from the Wilshire 5000 Index.
Nuvilex Pancreatic Cancer Trials Could Make "Cell-in-a-Box" Gold Standard
While many biotech and pharmaceutical companies are designing one drug after another to address specific health problems, Nuvilex, Inc.
Is a Pharmaceutical Company the Same as a Biotech?
"Pharmaceutical company" and "biotech" are terms that investors hear all the time -- but what's the difference? Are they essentially the same thing, or are they two entirely different types of drugmakers? The answer is more confusing that you may think.
Fitch Rates Indianapolis Bond Bank, IN's Downtown TIF Rev Bonds 'AA'; Outlook Stable
Proceeds will be used to refund outstanding series 2002G bonds and to finance various capital projects.
Eli Lilly workers volunteer overseas to help impoverished communities
The first of 200 Eli Lilly and Co. employees shipped out this week to take part in Lilly’s in-house version of the Peace Corps.
Adocia Announces Its Q1 2013 Revenues
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! Lyon, France, April 24, 2013 - Adocia , a biotechnology company specialized in the development of 'best-in-class' medicines from already approved therapeutic proteins, announces today its Q1 2013 revenues.
Eli Lilly & Co.'s Neutral Rating Reaffirmed at Zacks
's stock had its "neutral" rating reiterated by Zacks in a note issued to investors on Thursday, Stock Ratings Network reports.
Eli Lilly and Company Again Named One of s Top 50 Companies for Diversity
DiversityInc 's "Top 50 Companies for Diversity" is known as a leading assessment of diversity management globally.
Eli Lilly sues J&J for patent rights in Alzheimer's drug race
Eli Lilly & Co. sought to revoke a patent held by a Johnson & Johnson unit, arguing at a London court it might delay availability of a potential treatment for Alzheimer's. Both companies have drugs in development that use antibodies to target the build-up of plaque in patients' brains.
Disappointing earnings and weak sales outlooks hold stocks back; P&G and Eli Lilly fall
A subscriber slump at AT&T and a poor profit forecast at Procter & Gamble were among the disappointments investors were dealing with Wednesday.
Eli Lilly's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Ladies and gentlemen, thank you for standing by and welcome to the Q1 Earnings Call 2013.
Drugmaker Lilly's 1Q profit up, tops expectations
Shares of Eli Lilly rose in premarket trading Wednesday after the drug maker reported better-than-expected earnings for the first quarter and said regulators had agreed to a priority review of its potential stomach cancer treatment.